ArticleFrontiers in cardiovascular medicine2026
Revisiting the Ross operation: early results from a new Ross program at a cardiovascular center in South America.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Aortic valve disease in young adults remains challenging due to long life expectancy and the need for durable, anticoagulation-free solutions. The Ross procedure offers excellent hemodynamics and long-term durability but is underutilized in Latin America because of its technical complexity and limited homograft availability. Methods: We conducted an observational study including all adult patients undergoing the Ross procedure between July 2024 and April 2026 at Hospital Clínico UC-Christus. Demographics, clinical history, surgical indications, operative details, complications, and echocardiographic follow-up were analyzed. Results: 29 consecutive patients were included (13.8% female; range: 21-61). Main surgical indications were severe aortic stenosis (34.5%), mixed lesions (34.5%) and severe aortic regurgitation (27.6%); 86.2% had bicuspid aortic valves. Associated procedures were performed in 24.1% of cases. Median cross-clamp and cardiopulmonary bypass times were 205 and 230 min, respectively. Early complications included perioperative stroke in 3 patients (10.3%; all ischemic, two recovered with mRS: 0-1 and one with mRS: 3). Early echocardiography follow-up showed no neoaortic regurgitation in 18 patients, trivial in 9, and mild in 2, with a median neoaortic gradient of 4.0 mmHg and neopulmonary gradient of 2.0 mmHg. No patient developed severe autograft or homograft regurgitation. During a median follow-up of 295 days (range: 30-662), no deaths were observed. There was 1 reintervention due to homograft endocarditis. Conclusion: Implementation of a dedicated Ross program in a high-complexity Latin American center is feasible and was associated with acceptable early postoperative outcomes. These findings support feasibility and short-term safety only; longer follow-up and larger cohorts are required before conclusions can be drawn regarding durability or wider safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.